AU765214B2 - Methods for treating diabetes by inhibiting gdf-8 - Google Patents
Methods for treating diabetes by inhibiting gdf-8 Download PDFInfo
- Publication number
- AU765214B2 AU765214B2 AU41832/99A AU4183299A AU765214B2 AU 765214 B2 AU765214 B2 AU 765214B2 AU 41832/99 A AU41832/99 A AU 41832/99A AU 4183299 A AU4183299 A AU 4183299A AU 765214 B2 AU765214 B2 AU 765214B2
- Authority
- AU
- Australia
- Prior art keywords
- gdf
- subject
- inhibitor
- glut4
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8449098P | 1998-05-06 | 1998-05-06 | |
| US60/084490 | 1998-05-06 | ||
| PCT/US1999/010089 WO1999056768A1 (en) | 1998-05-06 | 1999-05-06 | Methods for treating diabetes by inhibiting gdf-8 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4183299A AU4183299A (en) | 1999-11-23 |
| AU765214B2 true AU765214B2 (en) | 2003-09-11 |
Family
ID=22185291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU41832/99A Ceased AU765214B2 (en) | 1998-05-06 | 1999-05-06 | Methods for treating diabetes by inhibiting gdf-8 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US6368597B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1075272B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4544742B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU765214B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2331410C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69941116D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2330062T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999056768A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7510851B2 (en) * | 2001-12-17 | 2009-03-31 | Metabolex, Inc. | Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US6908632B1 (en) | 2002-04-19 | 2005-06-21 | Pharmanex, Llc | Blood glucose modulating compositions and methods |
| AU2003267246A1 (en) * | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2003297460A1 (en) * | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| CA2558478A1 (en) * | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) * | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| MX2007008132A (es) * | 2004-12-30 | 2007-07-20 | Schering Plough Ltd | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes. |
| EP1864139A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| KR20120023787A (ko) | 2009-05-22 | 2012-03-13 | 가부시키가이샤 에리나 | 대사증후군의 예방제 및/또는 치료제 |
| WO2011087946A1 (en) | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| PH12013500315A1 (en) | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| MY177331A (en) * | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
| CN104931327B (zh) * | 2015-03-24 | 2018-10-19 | 重庆医科大学 | 微米级生物材料石蜡切片方法 |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| WO2020075845A1 (ja) * | 2018-10-12 | 2020-04-16 | シーシーアイホールディングス株式会社 | クラスiのグルコーストランスポーター(glut)の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物 |
| CN110408616B (zh) * | 2019-07-09 | 2021-06-15 | 中南民族大学 | GLUT4基因敲除的sgRNA、A549细胞系及其构建方法 |
| KR20220054608A (ko) | 2019-09-03 | 2022-05-03 | 노파르티스 아게 | ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998033887A1 (en) * | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| WO1999006559A1 (en) * | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| EE200200025A (et) * | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
-
1999
- 1999-05-06 ES ES99925578T patent/ES2330062T3/es not_active Expired - Lifetime
- 1999-05-06 DE DE69941116T patent/DE69941116D1/de not_active Expired - Lifetime
- 1999-05-06 CA CA002331410A patent/CA2331410C/en not_active Expired - Lifetime
- 1999-05-06 EP EP99925578A patent/EP1075272B1/en not_active Expired - Lifetime
- 1999-05-06 US US09/305,989 patent/US6368597B1/en not_active Expired - Lifetime
- 1999-05-06 AU AU41832/99A patent/AU765214B2/en not_active Ceased
- 1999-05-06 WO PCT/US1999/010089 patent/WO1999056768A1/en not_active Ceased
- 1999-05-06 JP JP2000546792A patent/JP4544742B2/ja not_active Expired - Lifetime
-
2001
- 2001-11-19 US US09/988,835 patent/US20020031517A1/en not_active Abandoned
-
2005
- 2005-06-16 US US11/155,336 patent/US20060121035A1/en not_active Abandoned
-
2008
- 2008-02-14 US US12/070,067 patent/US9150643B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,490 patent/US20160122424A1/en not_active Abandoned
-
2017
- 2017-08-24 US US15/685,582 patent/US20180134779A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998033887A1 (en) * | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160122424A1 (en) | 2016-05-05 |
| HK1038497A1 (en) | 2002-03-22 |
| US20020031517A1 (en) | 2002-03-14 |
| AU4183299A (en) | 1999-11-23 |
| CA2331410C (en) | 2009-07-14 |
| DE69941116D1 (de) | 2009-08-27 |
| US20180134779A1 (en) | 2018-05-17 |
| ES2330062T3 (es) | 2009-12-03 |
| US9150643B2 (en) | 2015-10-06 |
| JP2002513768A (ja) | 2002-05-14 |
| EP1075272B1 (en) | 2009-07-15 |
| WO1999056768A1 (en) | 1999-11-11 |
| CA2331410A1 (en) | 1999-11-11 |
| JP4544742B2 (ja) | 2010-09-15 |
| US6368597B1 (en) | 2002-04-09 |
| US20090035297A1 (en) | 2009-02-05 |
| EP1075272A1 (en) | 2001-02-14 |
| US20060121035A1 (en) | 2006-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9150643B2 (en) | Methods for treating diabetes | |
| EP1147413B1 (en) | Growth differentiation factor inhibitors and uses therefor | |
| Flyvbjerg et al. | Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody | |
| US7439333B2 (en) | Vascular endothelial growth factor 2 | |
| JP3854307B2 (ja) | 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害 | |
| JP4863548B2 (ja) | 結合組織増殖因子のモジュレーション、調節および抑制による腎障害の検出、予防および治療方法 | |
| US5723115A (en) | Inhibition of adipose tissue development and obesity | |
| Pankewycz et al. | Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells | |
| RU2322261C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
| US5821218A (en) | Regeneration of kidney tissue and use of autocrine growth factors | |
| Strissel et al. | Role of serum amyloid A as an intermediate in the IL-1 and PMA-stimulated signaling pathways regulating expression of rabbit fibroblast collagenase | |
| JP6667437B2 (ja) | 最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定 | |
| US20080221057A1 (en) | Secreted protein ccdc80 regulates adipocyte differentiation | |
| US7101845B2 (en) | Methods of modulating β cell function | |
| HK1038497B (en) | Methods for treating diabetes by inhibiting gdf-8 | |
| RU2197262C2 (ru) | Лиганд notch | |
| US20060234910A1 (en) | Methods for the treatment of insulin resistance and disease states characterized by insulin resistance | |
| WO1994009809A1 (en) | Method for preventing or treating liver disease | |
| Wang et al. | Rearrangement of S-100 immunoreactive Langerhans' cells in human psoriatic skin treated with peptide T |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |